Trial Profile
A Randomized Multicenter Phase III Study of Cisplatin Plus Radiotherapy Compared to Cetuximab Plus Radiotherapy in Locally Advanced Head and Neck Cancer
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 28 Mar 2024
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary) ; Cisplatin (Primary)
- Indications Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Mouth neoplasm; Oropharyngeal cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms ARTSCANIII
- 28 Mar 2024 Results (n=80) assessing the effect of weekly cisplatin or cetuximab combined with radiotherapy on weight loss at 3 months after treatment published in the Head and Neck
- 24 Mar 2024 This trial has been discontinued in Sweden (Global end date: 10 Jan 2024).
- 01 Sep 2020 Status changed from active, no longer recruiting to completed.